 | Up a level |
2019
Fraser, G., Cramer, P., Demirkan, F., Silva, R. Santucci, Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M-S, Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., Karlsson, C., Hallek, M., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. and Chanan-Khan, A. (2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia, 33 (4). S. 969 - 981. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
2015
Cramer, P., Chanan-Khan, A., Demirkan, F., Fraser, G., Santucci Silva, R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. S., Loscertales, J., Bartlett, N. L., Avigdor, A., Rule, S., Sun, S., Mahler, M., Salman, M., Howes, A. and Hallek, M. (2015). IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY. Haematologica, 100. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078